IPO - CNS Pharmaceuticals, Inc.

Form Type: 424B4

Filing Date: 2025-05-14

Corporate Action: Ipo

Type: New

Accession Number: 000168316825003523

Filing Summary: CNS Pharmaceuticals, Inc. is offering securities including 325,000 shares of common stock, pre-funded warrants for 3,627,570 shares, and Series F common warrants for 3,952,570 shares, aimed at raising approximately $4.6 million in net proceeds. The pricing for the public offering is set at $1.265 per share. The common warrants are exercisable at $1.14 per share, while each pre-funded warrant has a nominal exercise price of $0.001 and grants immediate exercise rights. The offering is backed by A.G.P./Alliance Global Partners as the sole placement agent, which will use its best efforts to manage the sale of the securities but is not guaranteeing any minimum purchase. There is currently no established trading market for the warrants, and the expected delivery of the securities is around May 14, 2025. The offering concludes by May 30, 2025, unless the company's objectives are not achieved through this offering. The prospectus also highlights the company's focus on the development of pharmaceutical candidates targeting brain and central nervous system tumors, primarily Berubicin and TPI 287, aiming to provide new therapeutic options for glioblastoma patients. The document warns of high investment risks and mentions compliance with stock exchange requirements, alongside the potential for not raising sufficient interest in this public offering.

Form Type: CORRESP

Filing Date: 2025-05-12

Corporate Action: Ipo

Type: New

Accession Number: 000168316825003396

Filing Summary: CNS Pharmaceuticals, Inc. has filed a correspondence with the U.S. Securities and Exchange Commission, requesting the acceleration of the effective date of its Registration Statement on Form S-1, which concerns its initial public offering (IPO). The request is to make the registration effective at 9:30 a.m. Eastern Time on May 13, 2025, or as soon thereafter as practicable. This correspondence is submitted by A.G.P. / Alliance Global Partners, who is acting as the sole Placement Agent for this offering. The action indicates progress towards the company's efforts to go public, highlighting a significant step in the IPO process.

Form Type: S-1/A

Filing Date: 2025-05-12

Corporate Action: Ipo

Type: Update

Accession Number: 000168316825003362

Filing Summary: CNS Pharmaceuticals, Inc. has filed Amendment No. 1 to Form S-1 Registration Statement under the Securities Act of 1933 as of May 12, 2025, to facilitate an initial public offering of up to 6,250,000 shares of common stock along with accompanying Series F warrants and pre-funded warrants. The company aims to raise capital for the development of its anti-cancer drug candidates, TPI 287 and Berubicin, which target brain and central nervous system tumors with potential FDA approval on the horizon. The offering follows positive but inconclusive clinical data for Berubicin against standard treatments. The company is classified as an emerging growth company and outlines potential risks related to market acceptance and competition from existing therapies.

Form Type: S-1

Filing Date: 2025-04-14

Corporate Action: Ipo

Type: New

Accession Number: 000168316825002548

Filing Summary: CNS Pharmaceuticals, Inc. is filing a registration statement under the Securities Act of 1933 for the offering of up to 5,223,880 shares of common stock and associated warrants. The offering is intended to commence as soon as practicable after the effective date of the registration statement. Common stock and warrants will be issued separately but will be purchased together. The proposed pricing for the offering is based on an assumed combined public offering price of $1.34 per share. The securities are targeted for a continuous offering under Rule 415. CNS Pharmaceuticals, being classified as an emerging growth company, will comply with reduced public reporting requirements. The company's focus is on developing anti-cancer drug candidates, specifically TPI 287 and Berubicin, aimed at treating CNS tumors. Berubicin has shown promise in clinical trials for Glioblastoma Multiforme. The stock is currently traded on the Nasdaq under the symbol CNSP. The last reported sale price was $1.34 per share as of April 11, 2025. The offering will end no later than April 30, 2025, and a single closing for the sale of securities is expected with investors funding the purchase. The placement agent engaged is A.G.P./Alliance Global Partners, and they will use reasonable efforts to arrange the sale of securities in this offering. The clinical and market environment, particularly regarding the promising outcomes of Berubicin, positions CNS Pharmaceuticals favorably for potential approval and market entry.

Form Type: CORRESP

Filing Date: 2025-04-14

Corporate Action: Ipo

Type: New

Accession Number: 000168316825002549

Filing Summary: CNS Pharmaceuticals, Inc. requests the acceleration of the effective date for their Registration Statement on Form S-1, file number 333-286529, to be declared effective on April 16, 2025, at 5:00 P.M. (Eastern Time). This request is made pursuant to Rule 461 of the Securities Act of 1933. The company asks for notification of the effectiveness via a telephone call to their counsel, Cavas Pavri, and requests written confirmation of this effectiveness.

Form Type: DRS

Filing Date: 2025-04-07

Corporate Action: Ipo

Type: New

Accession Number: 000168316825002312

Filing Summary: CNS Pharmaceuticals, Inc. filed a confidential draft registration statement on Form S-1 with the SEC on April 7, 2025, related to an initial public offering (IPO) of securities. The company is offering up to 6,363,637 shares of common stock at an assumed combined public offering price of $1.10 per share, accompanied by Series F warrants to purchase the same number of common shares. Additionally, the company is offering pre-funded warrants for the purchase of an equivalent number of shares to prevent certain investors from exceeding ownership limits over 4.99% or 9.99% of outstanding shares. This prospectus includes the terms and conditions of the offering, a summary of the company’s background, information about its drug candidates TPI 287 and Berubicin, and highlights their clinical significance, particularly in treating aggressive brain cancers like Glioblastoma. The document outlines their current status in clinical trials and discusses existing intellectual property arrangements, including collaborations aimed at enhancing their drug development efforts. The offering period is expected to conclude by April 30, 2025, with no minimum offering amount required to close the offering.